Summary
Immunethep has developed, patented (WO/2015/189422), and successfully undergone preclinical trials for a new breakthrough vaccine (PNV-Paragon Novel Vaccine). It protects against bacterial infections caused by 5 different bacteria: S. aureus, S. pneumoniae, K. pneumoniae, E. coli and GBS. Our innovation relies on the discovery of a virulence and immunosuppressive mechanism common to these pathogens. The bacteria excrete a highly immunosuppressive protein designated as glyceraldehyde-3-phosphate dehydrogenase (GAPDH), which disables the host immune response to infection. PNV works by blocking bacterial GAPDH, while not reacting to human GAPDH, allowing the host immune system to fight infection and eliminate the bacteria. Preclinical trials demonstrated high levels of efficacy against any of the 5 bacteria with an excellent safety profile. PNV is the world’s first vaccine not only to prevent multiple bacterial infections but for all invasive serotypes, including multi-resistant strains.
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/190152193 |
| Start date: | 01-01-2023 |
| End date: | 30-06-2025 |
| Total budget - Public funding: | 7 400 192,50 Euro - 2 499 999,00 Euro |
Cordis data
Original description
Immunethep has developed, patented (WO/2015/189422), and successfully undergone preclinical trials for a new breakthrough vaccine (PNV-Paragon Novel Vaccine). It protects against bacterial infections caused by 5 different bacteria: S. aureus, S. pneumoniae, K. pneumoniae, E. coli and GBS. Our innovation relies on the discovery of a virulence and immunosuppressive mechanism common to these pathogens. The bacteria excrete a highly immunosuppressive protein designated as glyceraldehyde-3-phosphate dehydrogenase (GAPDH), which disables the host immune response to infection. PNV works by blocking bacterial GAPDH, while not reacting to human GAPDH, allowing the host immune system to fight infection and eliminate the bacteria. Preclinical trials demonstrated high levels of efficacy against any of the 5 bacteria with an excellent safety profile. PNV is the world’s first vaccine not only to prevent multiple bacterial infections but for all invasive serotypes, including multi-resistant strains.Status
SIGNEDCall topic
HORIZON-EIC-2022-ACCELERATOROPEN-01Update Date
31-07-2023
Images
No images available.
Geographical location(s)
